A Transformative Alliance in Infectious Disease Diagnostics
In a groundbreaking move that will revolutionize the landscape of infectious disease diagnostics, Quest Diagnostics (NYSE: DGX) has finalized its acquisition of the U.S. laboratory services business of Oxford Immunotec Global PLC (Nasdaq: OXFD). This strategic alliance marks a significant advancement in the fight against infectious diseases, bringing together two industry leaders with a shared commitment to delivering unparalleled diagnostic solutions.
Expanding the Diagnostic Arsenal: T-SPOT.TB and Accutix
With this acquisition, Quest Diagnostics’ portfolio of innovative infectious disease testing services is bolstered by the addition of the T-SPOT.TB tuberculosis and Accutix tick-borne disease testing services. These cutting-edge technologies provide clinicians with powerful tools for accurate and timely diagnosis, enabling them to make informed decisions and implement effective treatment strategies.
A Long-Term Partnership for Innovation
Quest Diagnostics and Oxford Immunotec: a transformative alliance in infectious disease diagnostics
- T-SPOT.TB and Accutix testing services have been added to the Quest Diagnostics portfolio
- Long-term supply agreement for T-SPOT.TB test kits and accessories
- Strategic collaboration to drive continued growth of T-SPOT.TB testing in the US
- Physicians with the ability to choose through the continued offering of QuantiFERON TB tests
- T-SPOT.TB test recognized for superior accuracy and ease of use by the main medical associations
As part of the transaction, Oxford Immunotec will continue to supply T-SPOT.TB test kits and accessories to Quest Diagnostics under a long-term agreement. This ongoing collaboration ensures the seamless availability of these essential diagnostic tools, fostering a continuous flow of innovation and advancements in the field.
Strategic Alignment for T-SPOT.TB Growth
Beyond the supply agreement, Quest Diagnostics and Oxford Immunotec have forged a strategic collaboration to drive the continued growth of T-SPOT.TB testing in the United States. This alliance combines the strengths of both organizations, leveraging their expertise and resources to expand access to this vital diagnostic tool.
Empowering Physicians with Choice: QuantiFERON TB
Recognizing the importance of physician choice, Quest Diagnostics will continue to offer QuantiFERON TB testing services. This comprehensive approach empowers clinicians with a range of options, enabling them to select the most appropriate diagnostic test based on individual patient needs and preferences.
Blood-Based TB Testing: A Paradigm Shift
Quest Diagnostics and Oxford Immunotec: a transformative alliance in infectious disease diagnostics
- T-SPOT.TB and Accutix testing services have been added to the Quest Diagnostics portfolio
- Long-term supply agreement for T-SPOT.TB test kits and accessories
- Strategic collaboration to drive continued growth of T-SPOT.TB testing in the US
- Physicians with the ability to choose through the continued offering of QuantiFERON TB tests
- T-SPOT.TB test recognized for superior accuracy and ease of use by the main medical associations
The T-SPOT.TB test, an interferon-gamma release assay (IGRA), represents a paradigm shift in the diagnosis of Mycobacterium tuberculosis infection and disease. Its superior accuracy and ease of use have led to its endorsement by leading medical associations, including the Infectious Diseases Society of America (IDSA). By making this advanced technology more widely available, Quest Diagnostics and Oxford Immunotec are playing a pivotal role in the fight against tuberculosis.
Quest Diagnostics: Empowering Health Outcomes
Quest Diagnostics, a global leader in diagnostic testing, is renowned for its commitment to empowering people to take proactive steps towards improved health outcomes. With its vast database of clinical lab results, Quest Diagnostics provides invaluable insights that illuminate new pathways for disease detection, treatment, and prevention. This acquisition further strengthens Quest Diagnostics’ position as a driving force in the healthcare industry.
Oxford Immunotec: A Global Force in Diagnostics
Quest Diagnostics and Oxford Immunotec: a transformative alliance in infectious disease diagnostics
- T-SPOT.TB and Accutix testing services have been added to the Quest Diagnostics portfolio
- Long-term supply agreement for T-SPOT.TB test kits and accessories
- Strategic collaboration to drive continued growth of T-SPOT.TB testing in the US
- Physicians with the ability to choose through the continued offering of QuantiFERON TB tests
- T-SPOT.TB test recognized for superior accuracy and ease of use by the main medical associations
Oxford Immunotec, a global diagnostics company, has established itself as a pioneer in the development and commercialization of proprietary tests for immune-regulated conditions. Its T-SPOT.TB test has gained widespread recognition and approval in over 50 countries, including the United States, Europe, Japan, and China. This acquisition underscores Oxford Immunotec‘s commitment to expanding its reach and making a meaningful impact on global health.
A Future of Precision and Innovation
The acquisition of Oxford Immunotec‘s U.S. laboratory services business by Quest Diagnostics marks a transformative chapter in the field of infectious disease diagnostics. This alliance brings together two industry leaders with a shared vision of delivering precision, innovation, and unparalleled patient care. As these organizations continue to collaborate, they will undoubtedly push the boundaries of diagnostic science, empowering clinicians and improving the lives of countless individuals worldwide.
